logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10369105 B1

PDFFull Text
Date of Patent:
Aug. 06, 2019

Filed:

Mar. 02, 2018

Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation

Applicant:

Veiled Therapeutics Llc, Etta, MS (US);

Inventors:

James D. McChesney, Etta, MS (US);

Igor Nikoulin, San Diego, CA (US);

Steve J. Bannister, Tampa, FL (US);

Douglas L. Rodenburg, Thaxton, MS (US);

Assignee:

Veiled Therapeutics LLC, Etta, MS (US);

Attorneys:

Hamilton Desanctis & Cha, LLP

Sam L. Nguyen

Primary Examiner:

Mark V Stevens

Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); A61K 9/127 (2006.01); A61K 31/337 (2006.01); A61K 31/357 (2006.01); A61K 31/365 (2006.01); A61K 31/366 (2006.01); A61K 31/427 (2006.01); A61K 31/475 (2006.01); A61K 31/575 (2006.01); A61K 31/704 (2006.01); A61K 31/4745 (2006.01); A61K 31/5685 (2006.01); A61K 31/7056 (2006.01); A61K 31/7068 (2006.01); A61K 31/7076 (2006.01);
U.S. Cl.
CPC ...
A61K 9/1275 (2013.01); A61K 9/0019 (2013.01); A61K 9/5123 (2013.01); A61K 31/337 (2013.01); A61K 31/357 (2013.01); A61K 31/365 (2013.01); A61K 31/366 (2013.01); A61K 31/427 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/5685 (2013.01); A61K 31/575 (2013.01); A61K 31/704 (2013.01); A61K 31/7056 (2013.01); A61K 31/7068 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); A61K 47/545 (2017.08);
Abstract

In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.

Find Patent Forward Citations

Loading…